Detalhe da pesquisa
1.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med;
388(4): 319-332, 2023 01 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36511784
2.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Lancet;
401(10373): 269-280, 2023 01 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36709073
3.
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Ann Hematol;
2024 Mar 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38438627
4.
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Future Oncol;
20(12): 717-726, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38088119
5.
Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study.
Acta Haematol;
146(5): 373-378, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37231838
6.
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary.
Future Oncol;
2023 01 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36617990
7.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol;
23(8): 1031-1043, 2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35810754
8.
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Haematologica;
107(10): 2408-2417, 2022 10 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35354247
9.
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Future Oncol;
18(27): 2987-2997, 2022 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35950489
10.
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
Br J Haematol;
194(1): 132-139, 2021 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33822368
11.
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Lancet;
395(10218): 132-141, 2020 01 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31836199
12.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet;
396(10262): 1563-1573, 2020 11 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33189178
13.
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
N Engl J Med;
379(19): 1811-1822, 2018 11 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30403938
14.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
N Engl J Med;
378(6): 518-528, 2018 02 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29231133
15.
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
BMC Cancer;
21(1): 659, 2021 Jun 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34078314
16.
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Am J Hematol;
96(9): 1120-1130, 2021 09 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34062004
17.
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Am J Hematol;
96(6): 708-718, 2021 06 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33755235
18.
Elotuzumab in the treatment of relapsed and refractory multiple myeloma.
Future Oncol;
17(13): 1581-1591, 2021 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33478270
19.
Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report.
Br J Haematol;
189(4): 689-693, 2020 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31994178
20.
A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
Br J Haematol;
190(5): 736-740, 2020 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32236950